What Real-World Data Reveals About Cardiovascular Therapy Persistence

Cardiovascular disease requires lifelong management, yet maintaining patients on therapy remains one of the biggest challenges facing pharmaceutical organizations.

Even the most effective treatments can only deliver outcomes when patients continue taking them as prescribed. However, many patient support programs are still built around a common misconception: that missed doses are primarily driven by forgetfulness.

Medisafe's analysis of more than +130 behavioral signals per patient across millions of managed doses tells a different story.

The data reveal that cardiovascular persistence is influenced by a combination of daily routines, treatment complexity, environmental factors, and patient-specific behaviors. More importantly, these influences follow predictable patterns that can be identified before adherence begins to decline.

Adherence Follows Predictable Behavioral Patterns

Across cardiovascular patient populations, Medisafe identified four behavioral trends that influence persistence:

• Adherence is strongest when medication-taking is anchored to established daily routines, particularly during morning hours.
• Patients demonstrate adherence fluctuations throughout the week, with engagement declining on weekends.
• Dosage behaviors vary across geographic regions, highlighting the impact of healthcare systems, cultural factors, and support networks.
• Treatment complexity increases adherence risk, with persistence declining as patients manage complex dosing requirements.

These findings demonstrate that adherence challenges often emerge long before a patient abandons therapy entirely.

Why Traditional Patient Support Programs Miss the Mark

Most patient support programs rely on fixed reminders, scheduled outreach, and standardized educational content. The problem is that adherence risk changes over time.

A patient navigating multiple cardiovascular therapies faces different challenges than a newly diagnosed patient taking a single medication. Likewise, a patient whose routine changes due to travel or work schedules requires more support than someone with highly consistent habits.

Without visibility into these behavioral shifts, patient support programs intervene too late or with the wrong type of engagement.

Treatment Complexity Creates Adherence Risk

Patients managing one or two therapies demonstrated adherence rates reaching 82%, while adherence steadily decreased as additional medications were added to the regimen.

The data also revealed meaningful differences across cardiovascular drug classes, with adherence varying by therapy type and treatment burden.

For pharmaceutical organizations, these insights demonstrate that long-term persistence is driven by behavior, not reminders. Improving outcomes requires visibility of the barriers that influence patient engagement across all therapy-specific treatment journeys.

Turning Behavioral Intelligence Into Better Outcomes

Built on more than +12 years of real-world patient behavior data, Medisafe helps pharmaceutical organizations identify adherence risk before therapy abandonment.

By analyzing behavioral signals, treatment complexity, engagement patterns, and real-world patient activity, Medisafe enables brands to deliver personalized support at moments when intervention has the greatest impact.

The result is stronger patient engagement, improved adherence, and greater long-term value across cardiovascular portfolios.

New Insights Into Cardiovascular Patient Behavior

Medisafe's latest cardiovascular adherence analysis explores how routines, geography, therapy burden, and treatment characteristics influence long-term persistence.

The findings offer pharmaceutical teams a deeper understanding of the behavioral drivers behind adherence and actionable opportunities to strengthen patient support programs.

‍

Want to see more of the behavioral patterns shaping persistence?

Book a Strategy Session.

‍